| Name | Title | Contact Details |
|---|
Worldwide Clinical Trials is a global CRO providing full-service drug development services to the pharmaceutical and biotechnology industries from Early Phase and Bioanalytical Sciences through Phase II and III trials to peri-approval studies. Our team offers clients a wealth of expertise in neuroscience, cardiovascular, inflammation, rare disease, and other therapeutic areas. We successfully manage clinical trials with our own staff across nearly 60 countries in North America, Latin America, Europe, Asia Pacific and Middle East. Our full-service capabilities enable us to meet particular trial requirements without compromising on science, safety or service. Bioanalytical • Method Transfer and Validation • Pharmacokinetic Analysis and Reporting Clinical Research Services • Clinical Pharmacology • Bridging Studies • Dyna-Bridging Studies • Drug-Drug Interactions • Pharmacodynamic Modeling Clinical Development • Protocol Development • Feasibility • Project Management • Medical Monitoring • Clinical Monitoring • Site Management • Data Management • Rater Training • Biostatistics and Data Analysis • Medical Writing • Regulatory Affairs • Quality Assurance • Drug and Supply Depots • Drug Safety Peri-Approval • Product Safety and Pharmacovigilance • Late-Stage Research • Registries and Observational Studies • Health Outcomes, Epidemiology and Risk Management
Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.
Unity Health System is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Unity Health System is based in Rochester, NY. You can find more information on Unity Health System at www.unityhealth.org
St. Joseph Healthcare is a Bangor, ME-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Assisted Living-Madison House is a Kirkland, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.